Sagimet Biosciences Inc. Series A Common Stock (SGMT) Stock
Key stats
- Market cap
- $809.07M
- Price / Earnings ratio
- -14.4x
- EPS (TTM)
- -$1.29
- Volume
- Loading
- 52-week high
- $11.45
- 52-week low
- $4.50
Source: third-party data provider, as of November 13, 2026
Compare with SGMT
Recent news

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
SGMT

After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
SGMT

Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
SGMT

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
SGMT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 63.47
- MACD 12/26/9
- 0.33
- EMA 9 of MACD
- 0.17
- MACD histogram
- 0.16
- SMA 50
- $9.89
- Price above SMA 50
- EMA 50
- $9.70
- Price above EMA 50
- SMA 200
- $7.66
- Price above SMA 200
- EMA 200
- $8.01
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
SGMT

After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
SGMT

Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
SGMT

Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
Sagimet Biosciences Eyes U.S. Phase III Acne Study After Positive China Data
SGMT

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher
SGMT

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade
SGMT

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?
SGMT

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?
SGMT

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?
SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?
SGMT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Sagimet Biosciences Inc. Series A Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. David A. Happel | CEO, President & Director | 1962 |
| Mr. Thierry Chauche | CFO & Principal Accounting Officer | 1976 |
| Ms. Elizabeth Rozek Esq., J.D. | Chief Legal & Administrative Officer | 1972 |
| Mr. Urs Greber Ph.D. | Co-Founder | — |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder | — |
| Dr. Marie O'Farrell Ph.D. | Chief Scientific Officer | — |
| Mr. Robert D'Urso | Senior Vice President of New Products | — |
| Dr. Andreas Grauer M.D. | Chief Medical Officer | 1961 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 63.47
- MACD 12/26/9
- 0.33
- EMA 9 of MACD
- 0.17
- MACD histogram
- 0.16
- SMA 50
- $9.89
- Price above SMA 50
- EMA 50
- $9.70
- Price above EMA 50
- SMA 200
- $7.66
- Price above SMA 200
- EMA 200
- $8.01
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
7 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $7.00
- Average
- $22.24
- High
- $38.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | +0.0 | -24.5 | -26.7 | -52.0 | +7.6 | +43.0 | ||||||
| 2024 | +77.9 | -38.7 | -10.0 | -25.4 | +29.7 | -34.0 | +6.3 | -11.5 | -6.4 | +65.1 | +6.8 | -16.0 |
| 2025 | -2.0 | -20.2 | -5.5 | +33.7 | -9.7 | +118.3 | +8.2 | -9.0 | -6.8 | +22.1 | -10.4 | -12.9 |
| 2026 | -5.3 | -8.3 | -8.6 | +53.2 | -4.2 | +7.5 | -4.7 | +43.5 | -5.9 | +5.9 | +17.8 |



